Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00067808 · FLOW

Participant flow

Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS) · Source last updated 2012-08-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    10 mg/m2 by vein (IV) over 1 hour daily for 10 days
    id
    FG000
    title
    Decitabine 10 mg/m2 IV
  2. description
    20 mg/m2 IV over 1 hour daily for 5 days
    id
    FG001
    title
    Decitabine 20 mg/m2 IV
  3. description
    20 mg/m2 subcutaneous (SQ) daily for 5 days
    id
    FG002
    title
    Decitabine 20 mg/m2 SQ
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        17
      2. group Id
        FG001
        num Subjects
        93
      3. group Id
        FG002
        num Subjects
        14
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        17
      2. group Id
        FG001
        num Subjects
        93
      3. group Id
        FG002
        num Subjects
        14
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
Enrollment of 128 patients: 1 patient withdrew consent prior to treatment; 3 did not meet eligibility requirement for a total of 124 evaluable patients.
recruitment Details
Recruitment Period 6/4/03 - 5/18/09; all patients were registered at The University of Texas M.D. Anderson Cancer Center.
Complete source fields
groups
  1. description
    10 mg/m2 by vein (IV) over 1 hour daily for 10 days
    id
    FG000
    title
    Decitabine 10 mg/m2 IV
  2. description
    20 mg/m2 IV over 1 hour daily for 5 days
    id
    FG001
    title
    Decitabine 20 mg/m2 IV
  3. description
    20 mg/m2 subcutaneous (SQ) daily for 5 days
    id
    FG002
    title
    Decitabine 20 mg/m2 SQ
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        17
      2. group Id
        FG001
        num Subjects
        93
      3. group Id
        FG002
        num Subjects
        14
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        17
      2. group Id
        FG001
        num Subjects
        93
      3. group Id
        FG002
        num Subjects
        14
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
Enrollment of 128 patients: 1 patient withdrew consent prior to treatment; 3 did not meet eligibility requirement for a total of 124 evaluable patients.
recruitment Details
Recruitment Period 6/4/03 - 5/18/09; all patients were registered at The University of Texas M.D. Anderson Cancer Center.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice